Key facts
- This page summarizes Michael C. Ruettgers's Form 4 filing for GreenLight Biosciences Holdings, PBC.
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 26 Jul 2023, 16:41.
Michael C. Ruettgers - 24 Jul 2023 Form 4 Insider Report for GreenLight Biosciences Holdings, PBC
- Reporting relationship
- Member of 10% owner group
- Issuer ticker
- N/A
- Reported as of
- 24 Jul 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 26 Jul 2023, 16:41:22 UTC
- Prior SEC filing
- 08 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael Ruettgers
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Michael C. Ruettgers filed Form 4 for GreenLight Biosciences Holdings, PBC on 26 Jul 2023.
Change
- Previous filing in this sequence was filed on 08 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
GRNA
transaction
Common Stock
Other
- Transaction value
- Shares
- -206,629
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 24 Jul 2023
- Ownership
- See Footnote
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Michael C. Ruettgers is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
This Form 4 reports securities contributed by the Reporting Person in connection with the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 29, 2023, by and among GreenLight Biosciences Holdings, PBC, SW ParentCo, Inc. ("Parent"), and SW MergerCo, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), to Merger Sub in exchange for shares of Series A-2 Preferred Stock, par value $0.001 per share, of Parent pursuant to a Contribution and Exchange Agreement, dated May 29, 2016 (the "Contribution and Exchange Agreement"), between Parent and the Michael Ruettgers Revocable Trust. The price used to calculate the value of each share of Series A-2 Preferred Stock for purposes of the exchange was $0.40 per share, as determined pursuant to the terms of the Contribution and Exchange Agreement.
Footnote F2
Represents shares held by the Michael Ruettgers Revocable Trust as amended and restated. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.